Allison Christina Anderson

Mrs. Allison Christina Anderson

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Journal of Lipid Research
Verified
Journal Article
Open access
MBMarta Balog
Marta Balog
Allison Christina AndersonAllison Christina Anderson
Allison Christina Anderson
TGThiago Genaro-Mattos
Thiago Genaro-Mattos
ZKZeljka Korade
Zeljka Korade
Karoly MirnicsKaroly Mirnics
Karoly Mirnics
Polypharmacy, or the simultaneous use of multiple drugs to treat a single patient, is a common practice in psychiatry. Unfortunately, data on the health effects of commonly used combinations of medications are very limited. In this study, we therefore investigated the effects and interactions between two commonly prescribed psychotropic medications with sterol inhibiting side effects, trazodone (TRZ), an antidepressant, and aripiprazole (ARI), an antipsychotic. In vitro cell culture experiments revealed that both medications alone disrupted neuronal and astroglial sterol biosynthesis in dose-dependent manners. Furthermore, when ARI and TRZ were combined, exposure resulted in an additive 7-dehydrocholesterol (7-DHC) increase, as well as desmosterol (DES) and cholesterol decreases in both cell types. In adult mice, at baseline, we found that the three investigated sterols showed significant differences in distribution across the eight assessed brain regions. Furthermore, experimental mice treated with ARI or TRZ, or a combination of both medications for 8 days, showed strong sterol disruption across all brain regions. We show ARI or TRZ alone elevated 7-DHC and decreased DES levels in all brain regions, but with regional differences. However, the combined utilization of these two medications for 8 days did not lead to additive changes in sterol disturbances. Based on the complex roles of 7-DHC derived oxysterols, we conclude that individual and potentially simultaneous use of medications with sterol biosynthesis-inhibiting properties might have undesired side effects on the adult brain, with as yet unknown long-term consequences on mental or physical health.

21 October 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MBMarta Balog
Marta Balog
Allison Christina AndersonAllison Christina Anderson
Allison Christina Anderson
Marija HefferMarija Heffer
Marija Heffer
ZKZeljka Korade
Zeljka Korade
Karoly MirnicsKaroly Mirnics
Karoly Mirnics
Polypharmacy is commonly used to treat psychiatric disorders. These combinations often include drugs with sterol biosynthesis inhibiting side effects, including the antipsychotic aripiprazole (ARI), and antidepressant trazodone (TRZ). As the effects of psychotropic medications are poorly understood across the various tissue types to date, we investigated the effects of ARI, TRZ, and ARI + TRZ polypharmacy on the post-lanosterol biosynthesis in three cell lines (Neuro2a, HepG2, and human dermal fibroblasts) and seven peripheral tissues of an adult mouse model. We found that both ARI and TRZ strongly interfere with the function of 7-dehydrocholesterol reductase enzyme (DHCR7) and lead to robust elevation in 7-dehydrocholesterol levels (7-DHC) and reduction in desmosterol (DES) across all cell lines and somatic tissues. ARI + TRZ co-administration resulted in summative or synergistic effects across the utilized in vitro and in vivo models. These findings suggest that at least some of the side effects of ARI and TRZ are not receptor mediated but arise from inhibiting DHCR7 enzyme activity. We propose that interference with sterol biosynthesis, particularly in the case of simultaneous utilization of medications with such side effects, can potentially interfere with functioning or development of multiple organ systems, warranting further investigation.

6 June 2024 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
ZKZeljka Korade
Zeljka Korade
Allison Christina AndersonAllison Christina Anderson
Allison Christina Anderson
KSKanika Sharma
Kanika Sharma
KTKeri A. Tallman
Keri A. Tallman
HKHye-Young H. Kim
Hye-Young H. Kim
Karoly MirnicsKaroly Mirnics
Karoly Mirnics

28 August 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
ZKZeljka Korade
Zeljka Korade
Allison Christina AndersonAllison Christina Anderson
Allison Christina Anderson
MBMarta Balog
Marta Balog
KTKeri Ann Tallman
Keri Ann Tallman
NPNed Porter
Ned Porter
Karoly MirnicsKaroly Mirnics
Karoly Mirnics
The concurrent use of several medications is a common practice in the treatment of complex psychiatric conditions. One such commonly used combination is aripiprazole (ARI), an antipsychotic, and trazodone (TRZ), an antidepressant. In addition to their effects on dopamine and serotonin systems, both of these compounds are inhibitors of the 7-dehydrocholesterol reductase (DHCR7) enzyme. To evaluate the systemic and nervous system distribution of ARI and TRZ and their effects on cholesterol biosynthesis, adult mice were treated with both ARI and TRZ for 21 days. The parent drugs, their metabolites, and sterols were analyzed in the brain and various organs of mice using LC-MS/MS. The analyses revealed that ARI, TRZ, and their metabolites were readily detectable in the brain and organs, leading to changes in the sterol profile. The levels of medications, their metabolites, and sterols differed across tissues with notable sex differences. Female mice showed higher turnover of ARI and more cholesterol clearance in the brain, with several post-lanosterol intermediates significantly altered. In addition to interfering with sterol biosynthesis, ARI and TRZ exposure led to decreased ionized calcium-binding adaptor molecule 1 (IBA1) and increased DHCR7 protein expression in the cortex. Changes in sterol profile have been also identified in the spleen, liver, and serum, underscoring the systemic effect of ARI and TRZ on sterol biosynthesis. Long-term use of concurrent ARI and TRZ warrants further studies to fully evaluate the lasting consequences of altered sterol biosynthesis on the whole body.

10 April 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
ZKZeljka Korade
Zeljka Korade
Allison Christina AndersonAllison Christina Anderson
Allison Christina Anderson
MBMarta Balog
Marta Balog
KTKeri Ann Tallman
Keri Ann Tallman
NPNed Porter
Ned Porter
Karoly MirnicsKaroly Mirnics
Karoly Mirnics
Smith–Lemli–Opitz syndrome (SLOS) is a developmental disability arising from bi-allelic pathogenic variants in the 7-dehydrocholestrol reductase (DHCR7) enzyme and the accumulation of 7-dehydrocholesterol (7-DHC). 7-DHC spontaneously oxidizes and gives rise to cytotoxic oxysterols. Our recent high-throughput screening on Dhcr7-deficient Neuro2a cells identified hydroxyzine (HYZ) as a medication that could counteract the high levels of 7-DHC. We assessed the effects of HYZ in Dhcr7-deficient Neuro2a cells, neuronal cultures and glial cultures from Dhcr7T93M/T93M transgenic mice, and human dermal fibroblasts from patients with SLOS. LC-MS/MS biochemical analyses revealed a strong modulatory effect of HYZ on post-lanosterol biosynthesis across all four SLOS models. However, the HYZ-induced biochemical changes were complex, dose-dependent, and variable across the four SLOS models. Dhcr7-deficient Neuro2a cells showed decreased 7-DHC, 8-dehydrocholesterol (8-DHC), and desmosterol (DES) levels (all p < 0.01), while neuronal and glial cultures from Dhcr7T93M/T93M transgenic mice reported 8 significantly altered analytes (all p < 0.001). Human dermal fibroblast from patients with SLOS reacted to HYZ exposure with significantly decreased 7-DHC, 7-dehydrodesmosterol (7-DHD), and dihydrolanosterol (DHL) levels (p < 0.001), coupled with elevation in zymosterol (ZYM), zymostenol (ZYME), and 8-DHC (p < 0.001). Further evaluations are required to determine if the potentially beneficial effects of decreased 7-DHC, 7-DHD and DHL levels in SLOS models and patient biomaterials are counteracted by the rise in other post-lanosterol intermediates.

26 November 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
KTKeri A. Tallman
Keri A. Tallman
Allison Christina AndersonAllison Christina Anderson
Allison Christina Anderson
Karoly MirnicsKaroly Mirnics
Karoly Mirnics
NPNed A. Porter
Ned A. Porter
ZKZeljka Korade
Zeljka Korade
Cholesterol is an essential structural component of all cells, and the sterol biosynthetic pathway provides critical precursors for essential homeostatic molecules. Sterol biosynthesis can be disrupted by pathogenic variants in genes, as well as commonly prescribed medications. These medications disrupt post-lanosterol biosynthesis at different steps. We attempted to classify their actions based on the biochemical signatures of sterol intermediates. Our previous screening of the NIH Clinical Compound library of >1800 compounds in clinical use suggested that over 30 medications can disrupt post-lanosterol biosynthesis. Of these, we selected 11 compounds for follow up in a human dermal fibroblast model. Using LC-MS/MS we measured 13 post-lanosterol intermediates in control, DHCR7 +/- and DHCR7-/- human dermal fibroblasts exposed to cariprazine, nebivolol, rotigotine, buspirone, lurasidone, fluoxetine, hydroxyzine, amiodarone, spiroxamine, vilazodone and ziprasidone. All tested cells were exposed to 4 concentrations of each medication. We found in all fibroblasts, regardless of DHCR7 genetic makeup, sterol biosynthesis was inhibited by the tested medications. These medications could be classified in 6 groups based on the post-lanosterol profiles they produced – those that were 1) primarily DHCR7 inhibitors (cariprazine, nebivolol and rotigotine); 2) EBP inhibitors (fluoxetine); 3) combined DHCR7 and DHCR14 inhibitors (buspirone and lurasidone); 4) combined EBP and DHCR7 inhibitors (hydroxyzine); 5) combined EBP and DHCR24 inhibitors (amiodarone); and 6) multi-enzyme inhibitors (vilazodone, ziprasidone, spiroxamine). In addition, DHCR7 +/- fibroblasts responded with greater sterol profile disruptions to all medications, while DHCR7 fibroblasts from patients with Smith-Lemli-Opitz syndrome showed generally a more plateaued response. Knowing the inhibition profile-based classification of medications that have a sterol inhibiting side effect might ultimately translate into safety recommendations during pregnancy and could be critical for new drug development.